Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.
Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead M, Anderson LW, Polley E, Rubinstein L, Srivastava A, Wilsker D, Collins JM, Doroshow JH. Holbeck SL, et al. Among authors: rubinstein l. Cancer Res. 2017 Jul 1;77(13):3564-3576. doi: 10.1158/0008-5472.CAN-17-0489. Epub 2017 Apr 26. Cancer Res. 2017. PMID: 28446463 Free PMC article.
Compressing drug development timelines in oncology using phase '0' trials.
Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Kummar S, et al. Among authors: rubinstein l. Nat Rev Cancer. 2007 Feb;7(2):131-9. doi: 10.1038/nrc2066. Nat Rev Cancer. 2007. PMID: 17251919 Review.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. Kinders R, et al. Among authors: rubinstein l. Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Mol Interv. 2007. PMID: 18199854 Review.
Phase 0 clinical trials: conceptions and misconceptions.
Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH. Kummar S, et al. Among authors: rubinstein l. Cancer J. 2008 May-Jun;14(3):133-7. doi: 10.1097/PPO.0b013e318172d6f3. Cancer J. 2008. PMID: 18536551 Free PMC article. Review.
Designing phase 0 cancer clinical trials.
Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Murgo AJ, et al. Among authors: rubinstein l. Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560. Clin Cancer Res. 2008. PMID: 18559582 Free PMC article.
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team. Kinders RJ, et al. Among authors: rubinstein l. Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214. Clin Cancer Res. 2008. PMID: 18980982 Free PMC article.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Kummar S, et al. Among authors: rubinstein l. J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364967 Free PMC article. Clinical Trial.
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH; National Cancer Institute Phase 0 Working Group. Yang SX, et al. Among authors: rubinstein l. Cancer Biol Ther. 2009 Nov;8(21):2004-9. doi: 10.4161/cbt.8.21.9917. Epub 2009 Nov 25. Cancer Biol Ther. 2009. PMID: 19823047
434 results